logisticregressionpythonfromscratch| Baili Tianheng (688506.SH): The first subject was enrolled in the Phase III clinical trial of BL-M07D1 (HER2-ADC) for injection

Zhitong Finance APP News, Bailitianheng (688506logisticregressionpythonfromscratch.SH) issued an announcement and the company independently developedlogisticregressionpythonfromscratchThe Phase III clinical trial of the innovative biopharmaceutical injection BL-M07D1 (HER2-ADC) single agent for locally advanced or metastatic HER2-positive breast cancer has recently completed the enrollment of the first subject. BL-M07D1 is an ADC drug targeting HER2. Its indications are solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, gynecological tumors, and urinary system tumors.